A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies

Pharmacogenomics Journal

Volumn 9, Issue 2, 2009, Pages 137-146

  Sato, Y ^a,b   Laird, N M ^a   Nagashima, A ^c   Kato, R ^c   Hamano, T ^d   Yafune, A ^e   Kaniwa, N ^f   Saito, Y ^f   Sugiyama, E ^f   Kim, S R ^f   Furuse, J ^g   Ishii, H ^g   Ueno, H ^h   Okusaka, T ^h   Saijo, N ^g   Sawada, J I ^f   Yoshida, T ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d Hamano Statistical Analysis Ltd   (Japan)

^e Clinic Sendagaya   (Japan)

^f NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOMINANT GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG RESPONSE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PHARMACOGENOMICS; PRIORITY JOURNAL; QUESTIONNAIRE; RECESSIVE GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

COMPUTER SIMULATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; MONTE CARLO METHOD; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 63149101537     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2008.17     Document Type: Article

References (27)

1. Licinio J, Wong M. Pharmacogenomics: The Search for Individualized Therapies. Wiley: Weinheim (Germany), 2002.
2. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
3. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637-639.
4. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005; 107: 155-176.
5. US FDA. Guidance for Industry Pharmacogenomic Data Submissions. 2005.
6. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-945.
7. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
8. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6: 95-108.
9. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD. Genomewide association studies: Progress and potential for drug discovery and development. Nat Rev Drug Discov 2008; 7: 221-230.
10. Kruskal HW, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583-621.
11. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences, 2nd edn. McGraw-Hill: New York, 1988.
12. Mukerjee H, Robertson T, Wright FT. Comparison of several treatments with a control using multiple contrast. J Am Stat Assoc 1987; 82: 902-910.
13. Ruberg SJ. Contrasts identifying the minimum effective dose. J Am Stat Assoc 1989; 82: 816-822.
14. Yoshimura I, Wakana A, Hamada C. A performance comparison of maximum contrast methods to detect dose dependency. Drug Inf J 1997; 31 423-432.
15. Stewart H, Ruberg SJ. Detecting dose response with contrasts. Stat Med 2000; 19: 913-921.
16. Nishiyama H, Yanagihara H, Yoshimura I. SAS/IML program for computing probabilities related to maximum contrast methods. Jpn J Biometrics 2003; 24: 57-70, (in Japanese).
17. Wakana A, Yoshimura I, Hamada C. A method for therapeutic dose selection in a phase II clinical trial using contrast statistics. Stat Med 2007; 26: 498-511.
18. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992; 71: 169-180.
19. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-1633.
20. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 1994; 90: 2207-2212.
21. Vasku A, Soucek M, Znojil V, Rihacek I, Tschoplova S, Strelcova L et al. Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension. Kidney Int 1998; 53: 1479-1482.
22. Pereira TV, Nunes AC, Rudnicki M, Yamada Y, Pereira AC, Krieger JE. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: A role beyond M235T? Hypertension 2008; 51: 778-783.
23. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobulin A nephropathy in Caucasian patients. J Clin Invest 1997; 100: 814-820.
24. Genz A, Bretz F. Numerical computation of multivariate t-probabilities with application to power calculation of multiple contrasts. J Stat Comput Simulat 1999; 63: 361-378.
25. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-value Adjustment. Wiley: New York, 1993.
26. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Taylor & Francis: Sweden, 2000.
27. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.